JoinTechCell LLC, a company of the Nearmedic Group, has recently received the second international patent for the ESVIEF kit for isolating the stromal-vascular fraction from adipose tissue. The granting of the patent was preceded by an examination, successfully passed by the company. Earlier, the company had received a registration certificate for the use of ESVIEF in Russia and a patent in the Republic of Korea.
ESVIEF is a single-use sterile kit that allows one to isolate the stromal-vascular fraction from adipose tissue (lipoaspirate) by a step-by-step washing and treatment with an enzyme. The device provides for easy and convenient obtaining of necessary cells without losing their viability, and for their immediate use thereafter.
The final product, stromal-vascular fraction (SVF), is used mainly for the treatment of the musculoskeletal system diseases. The therapy involves obtaining stem cells from the patient’s adipose tissue and their subsequent introduction into the area of the pathological process, for example, in the joint, injured or affected by arthrosis. The procedure is highly effective and safe. SVF injections stimulate the processes of tissue regeneration, help to normalize immune processes and eliminate inflammation. In addition, SVF is now increasingly used for the treatment and correction of tissue defects (cartilage, ligaments, soft tissues) in plastic surgery, reconstructive medicine, urology, coloproctology.
«The technology of treatment with stromal-vascular fraction has long been used in European countries: Germany, France and Poland. The medical community is well familiar with this cellular technology. Currently, clinical studies are being conducted, which in the future will allow it to be used in new areas. The task of our company was to make the most effective, safe and standardized method of controlled isolation of SVF. With our device, the procedure becomes easier, does not require bulky equipment, and takes no more than 2 hours, » says Maria Petkova, Director of the Nearmedic Group Project Office and General Director of JoinTechCell LLC. «For any new medical device, the European market is one of the priorities, which is why the Nearmedic Group has decided to patent its developments in the EU. We regard passing all the examinations and obtaining the patent as a recognition of the high quality and uniqueness of our product,» she added.
For reference purposes
JoinTechCell LLC is a project company of the Nearmedik Group. The company was established in 2013. The organization focuses on the development of medical devices in the field of cellular technologies to be used in regenerative medicine.
The Nearmedic Group is a group of Russian companies created on the basis of the Nearmedic Plus LLC , a Russian pharmaceutical, biotechnological, and medical company operating since 1989. The group’s flagship brand is Kagocel, the market leader in the antiviral segment in Russia since 2014. The company also produces the Collost recovery complex, modern diagnostic test systems, xMark PLUS reagents for genetic identification and establishing of kinship. The Nearmedic Group also supplies the domestic market with laboratory equipment from leading world manufacturers, provides its servicing, and develops a network of multidisciplinary clinics.
Head of Public Relations and Corporate Communications Department
+7 (495) 741-49-89 ext. 1422
+7 (916) 581-37-32
+7 (915) 108-13-65